kabutan

OncoTherapy Science, Inc.(4564) Summary

4564
TSE Growth
OncoTherapy Science, Inc.
21
JPY
0
(0.00%)
Jan 29, 1:30 pm JST
0.13
USD
Jan 28, 11:30 pm EST
Result
PTS
outside of trading hours
20.4
Jan 29, 1:32 pm JST
Summary Chart Historical News Financial Result
PER
PBR
5.02
Yield
ー%
Margin Trading Ratio
4.45
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
21 JPY 0.13 USD
Previous Close Jan 28
21 JPY 0.13 USD
High Jan 29, 9:00 am
22 JPY 0.14 USD
Low Jan 29, 10:09 am
20 JPY 0.13 USD
Volume
29,483,000
Trading Value
0.61B JPY 3.98M USD
VWAP
20.64 JPY 0.14 USD
Minimum Trading Value
2,100 JPY 13 USD
Market Cap
7.91B JPY 0.05B USD
Number of Trades
62
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Mid
1-Year Average
240
1-Year High Jun 30, 2025
2,195
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 1,273,800 20,789,300 16.32
Jan 16, 2026 745,400 21,113,100 28.32
Jan 9, 2026 801,500 20,112,800 25.09
Dec 26, 2025 349,000 23,237,200 66.58
Dec 19, 2025 8,633,700 23,438,300 2.71
Company Profile
OncoTherapy Science, Inc. is a drug discovery venture originating from the Institute of Medical Science at the University of Tokyo. The company's main focus is on cancer gene analysis and the development of cancer therapeutics.
Sector
Pharmaceuticals
OncoTherapy Science, Inc. is a research and development-oriented venture that broadly engages in cancer drug development, from drug discovery research to clinical trials. The company promotes R&D in various areas including small molecule drugs, cancer peptide vaccines, and antibody drugs, with multiple ongoing clinical trials. Through its subsidiary, OncoTherapy Science also conducts large-scale cancer gene analysis tests and research and development of cancer immunotherapy, thus engaging in cancer precision medicine-related businesses. The company aims to realize personalized medicine through these efforts. OncoTherapy Science has established a staged revenue model including upfront payments, milestones, and royalties through partnerships with major pharmaceutical companies. The company is characterized by its long-term approach to research and development. As a result, its financial performance largely depends on the development progress of partnering pharmaceutical companies and the sales status of pharmaceuticals, which may not be reflected in short-term results in many cases.